AXSM Axsome Therapeutics, Inc. Stock Quote

AXSM [NASD]

Index	-	P/E	-	EPS (ttm)	-2.70	Insider Own	20.99%	Shs Outstand	37.31M	Perf Week	-1.26%
Market Cap	2.99B	Forward P/E	-	EPS next Y	-3.75	Insider Trans	0.00%	Shs Float	29.51M	Perf Month	-4.29%
Income	-98.50M	PEG	-	EPS next Q	-0.76	Inst Own	64.50%	Short Float	11.73%	Perf Quarter	4.37%
Sales	-	P/S	-	EPS this Y	-74.40%	Inst Trans	0.16%	Short Ratio	11.16	Perf Half Y	-7.84%
Book/sh	3.63	P/B	21.20	EPS next Y	-35.40%	ROA	-48.50%	Target Price	-	Perf Year	-14.81%
Cash/sh	5.21	P/C	14.78	EPS next 5Y	-	ROE	-63.10%	52W Range	35.44 - 109.53	Perf YTD	-5.54%
Dividend	-	P/FCF	-	EPS past 5Y	-42.80%	ROI	-	52W High	-29.73%	Beta	2.55
Dividend %	-	Quick Ratio	10.00	Sales past 5Y	-	Gross Margin	-	52W Low	117.16%	ATR	3.31
Employees	45	Current Ratio	10.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	45.20	Volatility	3.90% 4.22%
Optionable	Yes	Debt/Eq	0.35	EPS Q/Q	-10.60%	Profit Margin	-	Rel Volume	0.78	Prev Close	76.75
Shortable	Yes	LT Debt/Eq	0.35	Earnings	Nov 05 BMO	Payout	-	Avg Volume	310.14K	Price	76.96
Recom	1.70	SMA20	-4.41%	SMA50	-0.27%	SMA200	0.26%	Volume	242,609	Change	0.27%

Jan-08-21

Initiated

Jefferies

Buy

$129

Dec-16-20

Initiated

Mizuho

Buy

$120

Sep-29-20

Initiated

BofA Securities

Underperform

$66

Sep-10-20

Initiated

Morgan Stanley

Overweight

$102

Apr-28-20

Reiterated

H.C. Wainwright

Buy

$200 → $210

Apr-14-20

Initiated

Cowen

Outperform

$95

Dec-30-19

Reiterated

H.C. Wainwright

Buy

$170 → $200

Dec-17-19

Reiterated

H.C. Wainwright

Buy

$30 → $170

Dec-16-19

Reiterated

Guggenheim

Buy

$65 → $158

Oct-16-19

Initiated

Guggenheim

Buy

$48

Sep-18-19

Initiated

William Blair

Outperform

May-28-19

Initiated

SunTrust

Buy

May-23-19

Reiterated

H.C. Wainwright

Buy

$23 → $30

Apr-08-19

Initiated

SVB Leerink

Outperform

$25

Mar-15-19

Reiterated

H.C. Wainwright

Buy

$15 → $18

Oct-03-16

Resumed

Brean Capital

Buy

Dec-15-15

Initiated

Cantor Fitzgerald

Buy

Dec-14-15

Initiated

Ladenburg Thalmann

Buy

Jan-07-21 08:48AM	Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options Zacks
Jan-04-21 09:30AM	Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study Zacks
Dec-31-20 06:15AM	Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimers Disease Agitation GlobeNewswire
06:00AM	Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine GlobeNewswire
Dec-30-20 12:25AM	What Kind Of Shareholders Hold The Majority In Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shares? Simply Wall St.
Dec-17-20 05:25PM	Is AXSM A Good Stock To Buy Now? Insider Monkey
Dec-08-20 06:00AM	Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation GlobeNewswire
Dec-05-20 11:31AM	Why Is Axsome (AXSM) Up 15.2% Since Last Earnings Report? Zacks
Dec-02-20 06:00AM	Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression GlobeNewswire
Dec-01-20 06:00AM	Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder GlobeNewswire
Nov-06-20 11:31PM	Axsome Therapeutics, Inc. (AXSM) Q3 2020 Earnings Call Transcript Motley Fool
11:30AM	Axsome's (AXSM) Q3 Earnings In Line, Pipeline Progresses Zacks
Nov-05-20 07:00AM	Axsome Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire -6.99%
06:15AM	Axsome Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-04-20 07:03AM	Axsome Therapeutics and Veeva Systems Partner to Build Axsomes Digital-Centric Commercialization Platform Business Wire +7.62%
07:03AM	Axsome Therapeutics and Veeva Systems Partner to Build Axsomes Digital-Centric Commercialization Platform GlobeNewswire
Nov-03-20 07:00AM	Axsome Therapeutics to Present Data from the ADVANCE-1 Trial of AXS-05 in Alzheimers Disease Agitation at the 13th Clinical Trials on Alzheimers Disease (CTAD) Conference GlobeNewswire
Oct-28-20 07:00AM	Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020 GlobeNewswire
Oct-01-20 11:14AM	Did Axsome Therapeutics, Inc. (NASDAQ:AXSM) Insiders Buy Up More Shares? Simply Wall St.
Sep-29-20 12:00PM	Why Axsome Therapeutics Stock Is Sinking Today Motley Fool -5.47%
07:00AM	Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital GlobeNewswire
Sep-24-20 06:00AM	Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Demonstrating Rapid Onset of Action and Reduced Symptom Recurrence in the Acute Treatment of Migraine GlobeNewswire
Sep-22-20 12:19PM	Axsome Expedites Development Plan for Narcolepsy Candidate Zacks
Sep-21-20 07:00AM	Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting GlobeNewswire
Sep-17-20 07:00AM	Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the American Academy of Neurology Science Committee as Featured Presentation GlobeNewswire
Sep-15-20 12:46AM	Hedge Funds Keep Piling Into Axsome Therapeutics, Inc. (AXSM) Insider Monkey
Sep-14-20 06:00AM	Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive Disorder GlobeNewswire +13.73%
Sep-10-20 07:00AM	Axsome Therapeutics to Present New Data for AXS-05 in Major Depressive Disorder at the 33rd European College of Neuropsychopharmacology Congress GlobeNewswire
Sep-09-20 11:30AM	Axsome (AXSM) Down 10.4% Since Last Earnings Report: Can It Rebound? Zacks
Sep-08-20 07:00AM	Axsome Therapeutics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference GlobeNewswire
Sep-03-20 07:00AM	Axsome Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-31-20 07:00AM	Axsome Therapeutics Confirms Pivotal Status and Advancement of AXS-05 for the Treatment of Alzheimers Disease Agitation Based on Successful FDA Breakthrough Therapy Meeting GlobeNewswire
Aug-28-20 07:00AM	Axsome Therapeutics to Present Data from the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy at the SLEEP 2020 Annual Meeting GlobeNewswire
Aug-20-20 07:00AM	Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-07 for the Acute Treatment of Migraine GlobeNewswire
Aug-11-20 01:05PM	Axsome's (AXSM) Earnings Beat in Q2, Pipeline Progresses Zacks -5.10%
Aug-10-20 04:44PM	Why Axsome Therapeutics Stock Rose Today Motley Fool
07:05AM	Axsome Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
07:00AM	Axsome Therapeutics Announces Further Progress in AXS-05 Depression Clinical Program GlobeNewswire
Aug-05-20 07:00AM	Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy GlobeNewswire
Jul-30-20 07:00AM	Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020 GlobeNewswire
Jul-25-20 07:10AM	These Stocks Would Have Doubled Your Money Last Year Motley Fool
Jul-16-20 12:21PM	Were Hedge Funds Right About Axsome Therapeutics, Inc. (AXSM)? Insider Monkey
Jul-15-20 01:15PM	Steven Cohen Homes in on Otonomy GuruFocus.com
12:05PM	Axsome Focuses on Filling NDAs for Two CNS Candidates in 2020 Zacks
Jul-14-20 12:16PM	Axsome's NDA for Depressive Disorder Drug on Track in Q420 Zacks
Jul-13-20 07:00AM	Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive Disorder GlobeNewswire -7.59%
Jul-08-20 02:41PM	Here's Why Axsome Therapeutics Fell 20.4% in the First Half of 2020 Motley Fool
Jul-07-20 11:14AM	3 Perfect 10 Healthcare Stocks That Have Plenty of Growth on Tap TipRanks
Jul-03-20 03:19PM	What Kind Of Investors Own Most Of Axsome Therapeutics, Inc. (NASDAQ:AXSM)? Simply Wall St.
Jun-29-20 12:49PM	Axsome's AXS-05 Gets Breakthrough Therapy Tag for AD Agitation Zacks -10.99%
Jun-26-20 07:00AM	Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Alzheimers Disease Agitation GlobeNewswire +11.98%
Jun-15-20 12:24PM	Axsome Therapeutics, Inc. (AXSM): Are Hedge Funds Done Buying? Insider Monkey
Jun-07-20 11:30AM	Why Is Axsome (AXSM) Down 15.7% Since Last Earnings Report? Zacks
Jun-04-20 06:27PM	Edited Transcript of AXSM earnings conference call or presentation 8-May-20 12:00pm GMT Thomson Reuters StreetEvents
07:00AM	Axsome Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
May-29-20 01:38PM	Top Small Cap Stocks for June 2020 Investopedia
07:00AM	Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder at the 2020 American Society for Clinical Psychopharmacology Annual Meeting GlobeNewswire
May-26-20 12:57PM	Is Axsome Therapeutics a Buy? Motley Fool -5.23%
07:00AM	Axsome Therapeutics to Host 2020 Annual Meeting of Stockholders Virtually GlobeNewswire
May-23-20 07:36AM	Better Buy: Biogen vs. Axsome Therapeutics Motley Fool
May-19-20 06:04AM	What's Behind Axsome Therapeutics' Miracle Pipeline? Motley Fool
May-11-20 11:56AM	Axsome's (AXSM) Earnings Miss in Q1, Pipeline Progresses Zacks
May-09-20 02:00PM	Axsome Therapeutics, Inc. (AXSM) Q1 2020 Earnings Call Transcript Motley Fool
08:10AM	Why Jazz Pharmaceuticals' Symphony of Growth Is About to End Motley Fool
06:47AM	Is Axsome Therapeutics a Screaming Buy? Motley Fool
May-08-20 07:00AM	Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
May-03-20 03:39PM	Here's Why Axsome Therapeutics Rocketed 61.5% Higher in April Motley Fool
Apr-30-20 08:00AM	There May Be a New First-Line Treatment for Depression Motley Fool
07:00AM	Axsome Therapeutics to Report First Quarter 2020 Financial Results on May 8, 2020 GlobeNewswire
Apr-28-20 11:16AM	Axsome Shares Jump 25% on Alzheimer's Study Results GuruFocus.com
Apr-27-20 06:00AM	Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2/3 Trial in Alzheimers Disease Agitation GlobeNewswire +24.35%
Apr-07-20 12:37PM	Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study Zacks -6.87%
Apr-06-20 06:00AM	Axsome Therapeutics Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in the INTERCEPT Phase 3 Trial in the Early Treatment of Migraine GlobeNewswire
Apr-01-20 01:23PM	Edited Transcript of AXSM earnings conference call or presentation 12-Mar-20 12:00pm GMT Thomson Reuters StreetEvents -5.17%
Mar-31-20 05:05PM	Axsome's (AXSM) AXS-05 Fails to Meet Main Goal in TRD Study Zacks
04:52PM	5 Guru Stocks That Beat the Market GuruFocus.com
Mar-30-20 06:00AM	Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications GlobeNewswire -8.99%
Mar-29-20 08:53AM	Who Has Been Buying Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares? Simply Wall St.
Mar-28-20 09:23PM	Hedge Funds Have Never Been This Bullish On Axsome Therapeutics, Inc. (AXSM) Insider Monkey
Mar-23-20 12:17PM	Axsome Expedites Completion Timeline of AD Study on AXS-05 Zacks +17.48%
09:50AM	Is the Options Market Predicting a Spike in Axsome Therapeutics (AXSM) Stock? Zacks
Mar-20-20 07:00AM	Axsome Therapeutics Accelerates Completion of the ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimers Disease Agitation GlobeNewswire +17.06%
Mar-12-20 07:00AM	Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update GlobeNewswire -12.04%
Mar-05-20 07:00AM	Axsome Therapeutics Announces the Promotion of Mark Jacobson to Chief Operating Officer GlobeNewswire
Mar-04-20 07:00AM	Axsome Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 GlobeNewswire +5.40%
Mar-02-20 10:33AM	What's in Store for Axsome (AXSM) This Earnings Season? Zacks +13.94%
Feb-20-20 07:00AM	Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine GlobeNewswire
Feb-19-20 07:00AM	Axsome Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Jan-28-20 06:32PM	Axsome Therapeutics (AXSM) Gains But Lags Market: What You Should Know Zacks
Jan-23-20 09:34AM	Axsome (AXSM) Completes Patient Randomization in TRD Study Zacks
Jan-22-20 07:00AM	Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression GlobeNewswire
Jan-17-20 08:45AM	ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why Zacks
Jan-13-20 06:00AM	Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizers Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate GlobeNewswire
Jan-09-20 02:50PM	Top Biotech Stocks for Q1 2020 Investopedia
Jan-03-20 10:44AM	3 Top Drug Stocks to Own In 2020 InvestorPlace -6.53%
08:56AM	Do Options Traders Know Something About Axsome (AXSM) Stock We Don't? Zacks
Jan-02-20 07:57AM	The Zacks Analyst Blog Highlights: Cirrus Logic, CIRCOR, Axsome and Digital Turbine Zacks
Dec-31-19 09:26AM	Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study Zacks
08:42AM	Top 2019 Wall Street Stories That May Hit Headlines in 2020 Zacks
Dec-30-19 06:15AM	Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response GlobeNewswire

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical trial for the treatment of migraine; AXS-09 that has completed phase II clinical trial for the treatment of various CNS disorders; AXS-12, which has completed phase II clinical trial for the treatment of in narcolepsy; and AXS-14, an investigational medicine that is in phase III for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coleman Mark	Director	Jun 29	Buy	78.50	650	51,025	403,698	Jun 30 08:20 AM
Pizzie Nick	Chief Financial Officer	Jun 29	Buy	76.64	777	59,549	41,217	Jun 30 08:19 AM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience